Search Results
Département de Médecine Génomique des Tumeurs et des Cancers, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
Search for other papers by Anne-Paule Gimenez-Roqueplo in
Google Scholar
PubMed
Biomedical Research Networking Centre on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain
Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Mays Cancer Center at UTHSCSA, San Antonio, Texas, USA
Search for other papers by Patricia L M Dahia in
Google Scholar
PubMed
delays caused by the COVID-19 pandemic. In the intervening years, two international meetings related to pheochromocytomas (PCC) and paragangliomas (PGL) took place, Multiple Endocrine Neoplasia Workshop 2019 (in Houston) and 2021 (virtual). In 2019, the
Search for other papers by Liang Zhang in
Google Scholar
PubMed
Search for other papers by Tobias Åkerström in
Google Scholar
PubMed
Search for other papers by Kazhan Mollazadegan in
Google Scholar
PubMed
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Britt Skogseid in
Google Scholar
PubMed
Search for other papers by Joakim Crona in
Google Scholar
PubMed
Introduction Pheochromocytomas (PCCs) and paragangliomas (PGLs, together denoted as PPGLs) are rare endocrine tumors originating from chromaffin cells in the adrenal medulla (PCC) and extra-adrenal paraganglia (PGL). Sympathetic PPGLs secrete
Search for other papers by Arthur S Tischler in
Google Scholar
PubMed
Search for other papers by Judith Favier in
Google Scholar
PubMed
lacking for pheochromocytoma and paraganglioma (PGL). There are no human cell lines that faithfully represent these tumors although many attempts have been made to establish them. The failure may be explained in large part simply by the extremely low
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Roderick Clifton-Bligh in
Google Scholar
PubMed
of pheochromocytoma and paraganglioma. The ISP was originally established in 2005 under the auspices of the National Institutes of Health, Bethesda, USA in 2005. That year, the first meeting was held in the Holiday Inn hotel in Bethesda and brought
Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast Health & Social Care Trust, Belfast, UK
Search for other papers by Paul Benjamin Loughrey in
Google Scholar
PubMed
Search for other papers by Federico Roncaroli in
Google Scholar
PubMed
Search for other papers by Estelle Healy in
Google Scholar
PubMed
Search for other papers by Philip Weir in
Google Scholar
PubMed
Search for other papers by Madhu Basetti in
Google Scholar
PubMed
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
Search for other papers by Steven J Hunter in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Introduction Primary tumours of adenohypophyseal cells recently suggested to be redefined as pituitary neuroendocrine tumours (PitNETs) can rarely occur in association with paraganglioma (PGL) or phaeochromocytoma. These tumours may develop in
Search for other papers by Jared S Rosenblum in
Google Scholar
PubMed
Search for other papers by Herui Wang in
Google Scholar
PubMed
Search for other papers by Matthew A Nazari in
Google Scholar
PubMed
Search for other papers by Zhengping Zhuang in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Investigator Award), at the Sixth International Symposium on Pheochromocytoma/Paraganglioma (ISP) held in Prague, Czech Republic on 19–22 October 2022 which gathered the leading experts in every aspect of pheochromocytoma and paraganglioma (PPGL), including
Search for other papers by Susan Richter in
Google Scholar
PubMed
Search for other papers by Timothy J Garrett in
Google Scholar
PubMed
Search for other papers by Nicole Bechmann in
Google Scholar
PubMed
Department of Endocrinology, Royal North Shore Hospital, St Leonards, Australia
Search for other papers by Roderick J Clifton-Bligh in
Google Scholar
PubMed
Search for other papers by Hans K Ghayee in
Google Scholar
PubMed
diagnosis of pheochromocytoma/paraganglioma (PPGL) ( Eisenhofer & Peitzsch 2014 ). A triple quadrupole operating in the SRM/MRM mode is typically the most sensitive approach for measurements and is often employed when very low levels of an analyte are
Search for other papers by David Taïeb in
Google Scholar
PubMed
Search for other papers by Christelle Fargette in
Google Scholar
PubMed
Search for other papers by Abhishek Jha in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Nuclear medicine as a component of precision medicine This article is a summary of a plenary lecture presented at the 6th International Symposium on Pheochromocytoma/Paraganglioma (20 October 2022, Prague, Czech Republic), which explored the
Search for other papers by Robin Schürfeld in
Google Scholar
PubMed
Search for other papers by Christina Pamporaki in
Google Scholar
PubMed
Search for other papers by Mirko Peitzsch in
Google Scholar
PubMed
Search for other papers by Nada Rayes in
Google Scholar
PubMed
Search for other papers by Osama Sabri in
Google Scholar
PubMed
Center of Surgery, Department for Vascular Surgery, Diakonissen Hospital of Leipzig, Leipzig, Germany
Search for other papers by Silvio Rohm in
Google Scholar
PubMed
Search for other papers by Ronald Biemann in
Google Scholar
PubMed
Search for other papers by Benjamin Sandner in
Google Scholar
PubMed
Search for other papers by Anke Tönjes in
Google Scholar
PubMed
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Introduction Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors derived from chromaffin cells of the adrenal medulla or extraparaganglionic tissue ( Tischler 2008 ). Measurements of plasma-free normetanephrine and
Search for other papers by Francesca Amore in
Google Scholar
PubMed
Search for other papers by Rachele Garella in
Google Scholar
PubMed
Search for other papers by Alice Santi in
Google Scholar
PubMed
Search for other papers by Daniele Guasti in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Serena Martinelli in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Letizia Canu in
Google Scholar
PubMed
Search for other papers by Daniele Bani in
Google Scholar
PubMed
School of Pharmacy and Medical Science, Griffith University, Southport, Queensland, Australia
Faculty of Science and 1st Medical Faculty, Charles University, Prague, Czech Republic
Search for other papers by Jiri Neuzil in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Mario Maggi in
Google Scholar
PubMed
Search for other papers by Roberta Squecco in
Google Scholar
PubMed
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy
ENS@T Center of Excellence, Florence, Italy
Search for other papers by Elena Rapizzi in
Google Scholar
PubMed
Introduction Pheochromocytomas/paragangliomas (PPGLs) are rare catecholamine-secreting neuroendocrine tumours arising from the adrenal medulla or the extra-adrenal paraganglia. These tumours are characterized by a large spectrum of hereditary